<?xml version="1.0" encoding="UTF-8"?>
<ref id="B18">
 <label>18</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Sun</surname>
    <given-names>Y</given-names>
   </name>
   <name>
    <surname>Niu</surname>
    <given-names>W</given-names>
   </name>
   <name>
    <surname>Du</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Du</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>J</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Safety, Pharmacokinetics, and Antitumor Properties of Anlotinib, an Oral Multi-Target Tyrosine Kinase Inhibitor, in Patients With Advanced Refractory Solid Tumors</article-title>. 
  <source>J Hematol Oncol</source> (
  <year>2016</year>) 
  <volume>9</volume>(
  <issue>1</issue>):
  <fpage>105</fpage>. 
  <pub-id pub-id-type="doi">10.1186/s13045-016-0332-8</pub-id>
  <pub-id pub-id-type="pmid">27716285</pub-id>
 </mixed-citation>
</ref>
